|Bid||236.37 x 1200|
|Ask||240.00 x 1300|
|Day's Range||238.02 - 239.97|
|52 Week Range||163.08 - 247.64|
|Beta (5Y Monthly)||0.77|
|PE Ratio (TTM)||65.52|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Edwards Lifesciences (EW) closed the most recent trading day at $231.46, moving -0.67% from the previous trading session.
In 2000 Mike Mussallem was appointed CEO of Edwards Lifesciences Corporation (NYSE:EW). This analysis aims first to...
Edwards Lifesciences' (EW) HemoSphere all-in-one monitoring platform is gaining momentum on the back of a strong rollout that sees a full-market launch.
The Zacks Analyst Blog Highlights: Uber, AES, CIRCOR International, Edwards Lifesciences and Zynerba Pharmaceuticals
Some stock market bears have been waiting for a US recession for four years. Is 2020 the year they will finally be right or will they have to throw in the towel and join the bull's party?
Edwards Lifesciences (EW) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Allscripts (MDRX) is gaining steadily from strategic acquisitions and solid prospects in Sunrise EHR platform. However, integration risks remain a woe.
Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.
NextGen Healthcare (NXGN) is likely to boost presence in health management with CHC Strategies delivering quality medical care through the company's Population Health platform.
NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.
NuVasive (NUVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Nevro (NVRO) is gaining traction from strengthening international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.